Sector News

AstraZeneca snaps up ZS Pharma for $2.7 billion

November 6, 2015
Life sciences

AstraZeneca has unveiled plans to buy California-based ZS Pharma for $2.7 billion in a move that adds ballast to its cardiovascular and metabolic disease offering.

The transaction gives the drug giant access to the potassium-binding compound ZS-9, a potential best-in-class treatment for hyperkalaemia – a condition characterised by elevated levels of potassium in the blood linked with increased mortality in chronic kidney disease and coronary heart failure.

The drug is currently being reviewed by the US Food and Drug Administration, with an outcome expected by May 26 next year, while a submission in Europe is planned by the end of 2015. Current estimates for global peak year sales of ZS-9 exceed $1 billion, AZ said.

Under the terms of the deal, which have been unanimously approved by ZS Phama’s board of directors, AZ will acquire all of its outstanding capital stock for $90 per share in an all-cash transaction, which equates to some $2.7 billion. ZS Pharma, which has around 200 employees across three sites in California, Texas and Colorado, will then become a wholly owned subsidiary of AZ.

The transaction, which is expected to close by the end of the year, will not impact AZ’ financial guidance for 2015. The firm expects that the move will generate product sales from 2016, with minimal earnings dilution over 2016 and 2017, becoming accretive to core earnings from 2018.

Source: Pharma Times

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.